Table 3. Relationship between STMN1 expression and clinical factors (recurrence, clinical response).
|
STMN1 expression and recurrence in operable GC treated by adjuvant therapy (n=49) | ||||||
|---|---|---|---|---|---|---|
|
S-1-treated operable GC (n=35) |
5-FU-based medicine treated operable GC (n=14) |
|||||
| Recurrence | Low (n=10) | High (n=25) | P-value | Low (n=5) | High (n=9) | P-value |
| Absent | 5 | 4 | 0.0440a | 2 | 3 | 0.8037 |
| Present | 5 | 21 | 3 | 6 | ||
|
STMN1 expression and clinical response in inoperable GC (n=61) | ||||||
|---|---|---|---|---|---|---|
|
Paclitaxel+S-1-treated inoperable GC (n=39) |
Cisplatin+S-1- treated inoperable GC (n=22) |
|||||
| Clinical response | Low (n=13) | High (n=26) | P-value | Low (n=11) | High (n=11) | P-value |
| PR | 12 | 13 | 0.0141a | 8 | 7 | 0.4836 |
| SD | 1 | 9 | 1 | 3 | ||
| PD | 0 | 4 | 2 | 1 | ||
Abbreviations: PD=progressive disease; PR=partial response; SD=stable disease.
a
Significant difference P<0.05.